樂觀
$133.17
情境價格
$27.710
-1.349 (-4.87%)收盤時
Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products.
Hims & Hers Health Inc is currently a hold. The stock is trading at $28.07, which is below several analyst price targets, including $32 from JPMorgan and $35 from Barclays. However, the company is facing significant challenges, including a net loss of $142 million and a declining gross margin of 63.83%. The recent insider sale of 6,236 shares by the Chief Legal Officer, despite retaining a significant stake, raises concerns about management's confidence amid a 45% decline in stock price over the past year. The main risk is the ongoing class action lawsuit that could impact the company's reputation and financial standing.
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Hims Launches New Injectable and Oral Testosterone Replacement Therapies

Hims & Hers Health Faces Class Action Lawsuit Over FTC Allegations

Hims & Hers Faces Securities Class Action Amid FTC Allegations

Hims & Hers Health Class Action Reminder

Hims & Hers Health Inc. Class Action Lawsuit Announcement
Hims & Hers Health, Inc. operates as a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud-enabled pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of conditions, including primarily those related to sexual health, hair loss, hormone health, weight loss, dermatology, and mental health, as well as services such as comprehensive laboratory testing. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. It operates in the Healthcare sector (SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE industry).
Hims & Hers Health Inc is currently a hold. The stock is trading at $28.07, which is below several analyst price targets, including $32 from JPMorgan and $35 from Barclays. However, the company is facing significant challenges, including a net loss of $142 million and a declining gross margin of 63.83%. The recent insider sale of 6,236 shares by the Chief Legal Officer, despite retaining a significant stake, raises concerns about management's confidence amid a 45% decline in stock price over the past year. The main risk is the ongoing class action lawsuit that could impact the company's reputation and financial standing.

HIMS stock ended a three-day decline on peptide hopes: the Trump administration is reviewing a plan that could open a $2.2B market. $HIMS
展開
$HIMS The price is wasting time ... but it's running out of room. Imminent resolution. Weekly chart
展開


本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。